Data Analysis for Drug Repurposing for Effective 
Alzheimer’s Medicines – Salbutamol vs Long -acting 
Muscarinic Antagonists  
 
 
 [STUDY_ID_REMOVED]  
   
August  22, 202 2 
 
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 1 1. Comparison Details 
 
a. Intended aim(s) 
 To evaluate the comparative risk of dementia onset between patients treated with Salbutamol (albuterol) versus 
Long -acting muscarinic antagonists (LAMAs) – umeclidinium, aclidinium, tiotropi[INVESTIGATOR_1890], glycopyrolate, 
glycopyrronium – for  Chronic obstructive pulmonary disease (COPD). 
 b. Primary endpoint  
Incident dementia (i.e., Alzheimer’s disease, vascular dementia, senile, presenile, or unspecified dementia, or 
dementia in other diseases classified elsewhere) . 
 
2. Person responsible for implementation 
Seanna Vine  
 
3. Data Source (s) 
Medicare, 20 14-2018  
  
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 2 4. Study Design Diagram s 
 

!"#$%&'()*+&,-.(./.0 12.3,4-5'.6& [ZIP_CODE])(43.0 :;-')'&<.6=14/(56=&3)'/4-565/&46(4=.65'(' ><$%$'?
$

DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 4 5. Cohort Identification  
 
a. Cohort Summary 
This study will employ a new user, active comparator, observational cohort study design comparing Salbutamol versus 
Long -acting muscarinic antagonists (LAMAs). The patients will be required to have continuous enrollment during the 
baseline period of 365 days before initiation of study drugs (cohort entry/index date). Follow -up for the outcome 
(dementia) differs between analyses. Follow-up begins the day after drug initiation (analysis 1, 3, 4 ); 180 days after 
drug initiation (analysis 2). 
 
b. Key details regarding cohort creation 
 
Index date: 
• Day of initiation of new Salbutamol versus Long -acting muscarinic antagonists (LAMAs)  
 Inclusion criteria for analyses 1, 3, 4: 
• Aged > 65 years on the index date 
• 365 days enrollment in Medicare Parts A, B, and D with no HMO coverage  
• No use of Salbutamol versus Long -acting muscarinic antagonists (LAMAs) any time prior to index date (all 
available lookback approach with a minimum of 365 days) 
• No diagnosis of dementia any time prior to and including index date • No history of nursing home admission recorded in any time prior to and including index date • At least two claims with COPD diagnosis recorded in 365 days prior to index date (ICD-9 490, 491.0, 491.1, 
491.2x, 491.8, 491.9, 492.0, 492.8, 494.0, 494.1, 496 or ICD-10 J40, J41.0, J41.1, J41.8, J42, J43.0, J43.1, 
J43.2, J43.8, J43.9, J44.0, J44.1, J44.9, J47.0, J47.1, J47.9)  
 
Inclusion criteria for analysis 2: 
• Aged > 65 years on the index date 
• [ADDRESS_1284671] prior to index date 
• No use of Salbutamol versus Long -acting muscarinic antagonists (LAMAs), any time prior to index date (all 
available lookback approach with a minimum of 365 days) 
• No diagnosis of dementia any time prior to and including index date 
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 5 • No history of nursing home admission recorded in any time prior to and including index date 
• At least two claims with COPD diagnosis recorded in 365 days prior to index date (ICD -9 490, 491.0, 491.1, 
491.2x, 491.8, 491.9, 492.0, 492.8, 494.0, 494.1, 496 or ICD-10 J40, J41.0, J41.1, J41.8, J42, J43.0, J43.1, 
J43.2, J43.8, J43.9, J44.0, J44.1, J44.9, J47.0, J47.1, J47.9)  
• 180-day continuous use of Salbutamol versus Long -acting muscarinic antagonists (LAMAs) starting on the  
index date 
  
c. Flowchart of the study cohort assembly 
 
 
 
 
 
 
  

DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 6 6. Variables  
 
a. Exposure-related variables:  
 
Study drug:  
The study exposure of interest is initiation of Salbutamol 
Comparator: 
Long -acting muscarinic antagonists (LAMAs) – umeclidinium, aclidinium, tiotropi[INVESTIGATOR_1890], glycopyrolate, glycopyrronium 
 
b. Covariates: 
 
Demographics  
Age Region 
Gender  Calendar year of index date  
Race Low income subsidy 
  
Dementia risk factors  
Diabetes  Depression 
Obesity Anxiety 
Hypertension  Bipolar disorder  
Coronary artery disease Schizophrenia 
 
Markers for healthy behavior, frailty, healthcare use  
Smoking  Number of hospi[INVESTIGATOR_914326] C-reactive protein tests ordered 
Pneumococcal vaccination  Osteoporosis  
Herpes zoster vaccination Fractures 
Bone mineral density test Falls  
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 [ADDRESS_1284672] generic agents Use of supplemental oxygen 
Number of emergency room visits  Combined comorbidity score  
Number of outpatient visits  
 
COPD specific and other pulmonary relevant covariates 
Respi[INVESTIGATOR_914327]1 Interstitial lung disease, lung fibrosis, ARDS 
Tuberculosis  Acute Upper/ Lower Respi[INVESTIGATOR_914328]-1-antitrypsin deficiency  
Sarcoidosis Number of Pulmonologist  visits 
Pulmonary function t est  
 
COPD medication levels (a multi -category using hierarchical definition described below)[ADDRESS_1284673] (SAMA or SABA only):  One or more 
from [S albutamol , Fenoterol,  
Levalbuterol, Terbutaline, Ipratropi[INVESTIGATOR_1890],  
Oxitropi[INVESTIGATOR_1890]] but not any from [ADDRESS_1284674] (LAMA or LABA only):  One/more LABA 
[Arformoterol, Formoterol  
Indacaterol, Olodat erol, Salmeterol] OR  
one/more LAMA [Tiotropi[INVESTIGATOR_1890], Aclidinium, 
Glycopyrronium, Umeclidinium] but not both  
3. Dual therapy  LAMA+LABA:  One/more LABA [Arformoterol, 
Formoterol  
Indacaterol, Olodaterol, Salmeterol] AND  
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 8 One/more LAMA [Tiotropi[INVESTIGATOR_1890], Aclidinium, 
Glycopyrronium, Umeclidinium] but no inhaled 
corticosteroid  
ICS + LAMA: One/more inhaled corticosteroid 
[beclomethasone, budenoside, mometasone, 
fluticasone] AND 
One/more LAMA [Tiotropi[INVESTIGATOR_1890], Aclidinium, 
Glycopyrronium, Umeclidinium] but no LABA  
ICS + LABA:  One/more inhaled corticosteroid 
[beclomethasone, budenoside, mometasone, 
fluticasone] AND 
One/more LABA [Arformoterol, Formoterol 
Indacaterol, Olodaterol, Salmeterol] but no LAMA  
4. Triple therapy ( ICS + LAMA + LABA ) One/more inhaled corticosteroid [ beclomethasone, 
budenoside, mometasone, fluticasone] AND 
One/more LAMA [Tiotropi[INVESTIGATOR_1890], Aclidinium, 
Glycopyrronium, Umeclidinium] AND  
One/more LABA [Arformoterol, Formoterol 
Indacaterol, Olodaterol, Salmeterol]  
 
Comedication use 
Lithium Diuretics 
Anti-epi[INVESTIGATOR_643648]-epi[INVESTIGATOR_23698] (other than mood stabilizers) Lipid lowering drugs 
Atypi[INVESTIGATOR_914329]-insulin diabetes medications 
Benzodiazepi[INVESTIGATOR_643650]-norepi[INVESTIGATOR_914330]  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 9 Selective serotonin reuptake inhibitors 
Angiotensin II receptor blockers (ARBs)  
Tricyclic antidepressants (TCAs) 
Angiotensin converting enzyme inhibitors (ACEi)  
Typi[INVESTIGATOR_914331]-modifying antirheumatic drugs 
(DMARDs) 
Corticosteroids Antibiotics 
 
Comorbid conditions  
Atrial fibrillation Asthma 
Heart failure  Ischemic heart disease  
Stroke or transient ischemic attack Malignancy 
Peripheral vascular disease  Drug or alcohol abuse or dependence  
Hyperlipi[INVESTIGATOR_914332]-9, ICD -10, HCPCS, and NDC codes used to define the covariates listed above are available in Appendix A.  
 
c. Outcome variables and study follow-up:  
 
• Primary outcome: incident dementia, i.e., Alzheimer’s disease, vascular dementia, senile, presenile, or 
unspecified dementia, or dementia in other diseases classified elsewhere. Outcome will be defined by 1 inpatient 
claim or 2 outpatient claims in analysis 1, 2, 3. In analysis 4, the outcome will be defined by 1 inpatient or 1 
outpatient claims and 1 prescription claim for a symptomatic treatment [donepezil, galantamine, rivastigmine, and memantine] within 6 months of each other with outcome date assigned to second event in the sequence.  
• Secondary outcomes: Individual component: 
Alzheimer’s disease 
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 10  
Condition  ICD-9 and ICD -10 codes  
Alzheimer’s disease 331.0*, F00*, G30*  
Vascular dementia  290.4*, F01*  
Senile, presenile, or unspecified dementia 290.0*, 290.1*. 290.3*, 797*, F03*  
Dementia in other diseases classified elsewhere  331.1*, 331.2*, 331.7*, 294.1*, F02*  
 
For analysis 1,3, and [ADDRESS_1284675] date of the following events: 
• The first occurrence of the outcome of interest  
• The date of end of continuous registration in the database, • End of the study period, 
• Measured death event occurs, 
• The date of drug discontinuation, defined as the date of the last continuous treatment epi[INVESTIGATOR_8372] 
(Salbutamol and LAMAs) plus a defined grace period (i.e., [ADDRESS_1284676] prescription’s days’ 
supply in main analyses). 
 
For analysis 2, the follow-up will start [ADDRESS_1284677] date of the following events: 
• The first occurrence of the outcome of interest, unless otherwise specified for selected outcomes,  
• The date of end of continuous registration in the database, • End of the study period, 
• Measured death event occurs, 
• Maximum allowed follow-up time (1095 days) reached   
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 11 7. Propensity score analysis   
We will use a propensity-score (PS)3-based approach to account for measured confounding in this study. The PS will 
be calculated as the predicted probability of initiating the exposure of interest (i.e., the repurposing candidate) versus 
the reference drug conditional on baseline covariates using multivariable logistic regression constructed separately 
in each data source. On average, patients with similar PSs have similar distribution of potential confounders used to 
estimate the PS. Therefore, analyses conditioned on the PS provide effect estimates that are free from measured 
confounding. For all our analyses, initiators of each exposure of interest will be matched with initiators of the reference 
exposure based on their PS within each data source.[ADDRESS_1284678], the PS distributional overlap is provided between 
two groups before and after matching to ensure comparability of these groups.7 Next, balance in each individual 
covariate between two treatment groups is reported using standardized differences.8 
  
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 [ADDRESS_1284679]. Diff  (N = 76, 515) (N = 18, 974) (N = 18, 633) (N = 18,633) 
Demographics             
 Age, mean (SD)  74.4 (6.7)  74.9 (6.6) -7 74.9 (6.8) 74.9 (6.6)  0.2 
 Gender, n (%)              
 Male  
[ZIP_CODE] (44.7)  9622 (50.7)  -12.1 9399 (50.4)  9443 (50.7)  -0.5 
 Female  
[ZIP_CODE] (55.3)  9352 (49.3)  12.1 9234 (49.6)  9190 (49.3)  0.5 
 Race, n (%)              
 White  
[ZIP_CODE] (89)  [ZIP_CODE] (89.7)  -2.2 [ZIP_CODE] (89.8)  [ZIP_CODE] (89.7)  0.4 
 Black  4701 (6.1)  999 (5.3)  3.8 931 (5)  981 (5.3)  -1.2 
 Hispanic  895 (1.2)  197 (1)  1.3 209 (1.1)  195 (1) 0.7 
 Other  2800 (3.7)  756 (4)  -1.7 753 (4)  740 (4)  0.4 
 Region, n (%)              
 Northeast; n (%)  [ZIP_CODE] (16.9)  3858 (20.3)  -8.8 3901 (20.9)  3803 (20.4)  1.3 
 South; n (%)  [ZIP_CODE] (40.4)  7738 (40.8)  -0.9 7470 (40.1)  7559 (40.6)  -[ADDRESS_1284680]; n (%)  [ZIP_CODE] (25.7)  4337 (22.9)  6.7 4238 (22.7)  4281 (23)  -0.[ADDRESS_1284681]; n (%)  [ZIP_CODE] (16.9)  3028 (16)  2.6 3016 (16.2)  2978 (16)  0.6 
Other; n (%) 62 (0.1)  13 (0.1)  0.5 8 (0)  12 (0.1)  -0.9 
Calendar year of index 
date, n (%)             
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 13 2014 [ZIP_CODE] (27.6)  5664 (29.9)  -5.1 5515 (29.6)  5603 (30.1)  -1 
2015 [ZIP_CODE] (22.1)  4117 (21.7)  1 4098 (22)  4080 (21.9)  0.2 
2016 [ZIP_CODE] (17.6)  3308 (17.4)  0.5 3372 (18.1)  3282 (17.6)  1.3 
2017 [ZIP_CODE] (17.4)  2979 (15.7)  4.6 2951 (15.8)  2958 (15.9)  -0.1 
2018 [ZIP_CODE] (15.3)  2906 (15.3)  -0.1 2697 (14.5)  2710 (14.5)  -0.2 
Low income subsidy, n (%)  [ZIP_CODE] (20.2)  3492 (18.4)  4.5 3416 (18.3)  3430 (18.4)  -0.2 
Dementia risk factors, n 
(%)             
Diabetes  [ZIP_CODE] (34)  6496 (34.2)  -0.6 6331 (34)  6370 (34.2)  -0.4 
Obesity [ZIP_CODE] (19.1)  3559 (18.8)  0.9 3442 (18.5)  3486 (18.7)  -0.6 
Hypertension  
[ZIP_CODE] (81.9)  [ZIP_CODE] (82.8)  -2.3 [ZIP_CODE] (82.8)  [ZIP_CODE] (82.8)  -0.2 
Coronary artery disease  [ZIP_CODE] (38.5)  8138 (42.9)  -8.9 7942 (42.6)  7989 (42.9)  -0.5 
Depression  [ZIP_CODE] (17.1)  3139 (16.5)  1.4 3091 (16.6)  3071 (16.5)  0.3 
Anxiety  [ZIP_CODE] (17.5)  3112 (16.4)  2.9 3049 (16.4)  3041 (16.3)  0.1 
Bipolar disorder  1089 (1.4)  260 (1.4)  0.5 277 (1.5)  254 (1.4)  1 
Schizophrenia  162 (0.2)  30 (0.2)  1.2 28 (0.2)  29 (0.2)  -0.1 
Markers for healthy 
behavior, frailty, 
healthcare use              
Smoking, n (%)  
[ZIP_CODE] (47.7)  [ZIP_CODE] (54.4)  -13.5 [ZIP_CODE] (54.2)  [ZIP_CODE] (54.4)  -0.4 
Mammography, n (%)  [ZIP_CODE] (20.9)  3333 (17.6)  8.5 3263 (17.5)  3275 (17.6)  -0.2 
Colonoscopy, n (%)  7990 (10.4)  1918 (10.1) 1.1 1819 (9.8)  1876 (10.1)  -[ADDRESS_1284682], n 
(%) 5563 (7.3)  1488 (7.8)  -2.2 1440 (7.7)  1461 (7.8)  -0.4 
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 14 Influenza vaccination, n 
(%) [ZIP_CODE] (64.4)  [ZIP_CODE] (67.8)  -7 [ZIP_CODE] (68.1)  [ZIP_CODE] (67.7)  0.8 
Pneumococcal 
vaccination, n (%)  [ZIP_CODE] (40.8)  8082 (42.6)  -3.6 7935 (42.6)  7896 (42.4)  0.4 
Herpes zoster, n (%)  16 (0)  5 (0)  -0.4 7 (0)  4 (0)  0.9 
Bone mineral density, n 
(%) 7356 (9.6)  1716 (9)  2 1753 (9.4)  1682 (9)  1.[ADDRESS_1284683] 
prescriptions, mean (SD)  12.1 (5.8)  12.1 (5.8) 0.9 12 (5.7)  12 (5.8)  -0.4 
Number of emergency 
room visits, mean (SD)  0.9 (1.6)  0.8 (1.4) 9 0.8 (1.2) 0.8 (1.4) -1 
Number of outpatient 
visits, mean (SD)  11.6 (8.4)  12.2 (8.7) -6.8 12.2 (8.7) 12.1 (8.7)  0.8 
Number of 
hospi[INVESTIGATOR_602], mean (SD) 
0.3 (0.7) 0.4 (0.7) -4.4 0.4 (0.7) 0.4 (0.7) 0 
Number of physician 
office visits, mean (SD)  11.6 (8.4)  12.2 (8.7) -6.8 12.2 (8.7) 12.1 (8.7)  0.8 
Number of C -reactive 
protein tests ordered, 
mean (SD)  0.2 (0.8)  0.2 (0.8) -1 0.2 (0.8) 0.2 (0.8) 0.1 
Number of serum 
creatinine tests ordered, mean (SD)  
1.2 (2.1)  1.2 (2.1) -1.8 1.2 (2)  1.2 (2.1) 0.1 
Composite frailty score, 
mean (SD)  0.2 (0.1)  0.2 (0.1) -6 0.2 (0.1) 0.2 (0.1) -0.6 
Osteoporosis, n (%)  [ZIP_CODE] (13.7)  2664 (14)  -0.8 2695 (14.5)  2622 (14.1) 1.1 
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 15 Fractures, n (%)  5899 (7.7)  1347 (7.1)  2.3 1310 (7)  1314 (7.1)  -0.1 
Falls, n (%) 4903 (6.4)  1101 (5.8)  2.5 1060 (5.7)  1071 (5.7)  -0.3 
Use of supplemental 
oxygen, n (%) 2548 (3.3)  1124 (5.9)  -12.4 1083 (5.8)  1103 (5.9)  -0.5 
Combined comorbidity 
score, mean (SD)  3 (2.6)  3.2 (2.7) -8.8 3.2 (2.7) 3.2 (2.7) -0.8 
Comedication use, n (%)              
Lithium  104 (0.1)  31 (0.2)  -0.7 27 (0.1)  30 (0.2)  -0.4 
Anti-epi[INVESTIGATOR_914333]  962 (1.3)  233 (1.2)  0.3 230 (1.2)  226 (1.2)  0.2 
Anti-epi[INVESTIGATOR_23698] (other than 
mood stabilizers)  [ZIP_CODE] (16.6)  3012 (15.9)  1.9 2891 (15.5)  2939 (15.8)  -0.7 
Atypi[INVESTIGATOR_16709] 1468 (1.9)  364 (1.9)  0 357 (1.9)  353 (1.9)  0.2 
Benzodiazepi[INVESTIGATOR_1651]  [ZIP_CODE] (20.5)  3774 (19.9)  1.6 3728 (20)  3694 (19.8)  0.5 
Serotonin -norepi[INVESTIGATOR_153868]  4148 (5.4)  1090 (5.7)  -1.4 1056 (5.7)  1058 (5.7)  0 
Selective serotonin 
reuptake inhibitors  [ZIP_CODE] (18.4)  3371 (17.8)  1.7 3322 (17.8)  3310 (17.8)  0.2 
Tricyclic antidepressants 
(TCAs) 2824 (3.7)  615 (3.2)  2.5 599 (3.2)  603 (3.2)  -0.1 
Typi[INVESTIGATOR_16709]  280 (0.4)  55 (0.3)  1.3 46 (0.2)  55 (0.3)  -0.9 
Anticoagulants  [ZIP_CODE] (13.4)  3023 (15.9)  -7.1 2964 (15.9)  2971 (15.9)  -0.1 
Antiplatelet agents  [ZIP_CODE] (13.3)  2881 (15.2)  -5.5 2751 (14.8)  2827 (15.2)  -1.1 
Nitrates  8214 (10.7)  2245 (11.8)  -3.5 2186 (11.7)  2202 (11.8)  -0.3 
Lipid lowering drugs  
[ZIP_CODE] (59.9)  [ZIP_CODE] (62.6)  -5.5 [ZIP_CODE] (62)  [ZIP_CODE] (62.6)  -1.2 
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 16 Non-insulin diabetes 
medications [ZIP_CODE] (19.3)  3652 (19.2)  0.1 3513 (18.9)  3575 (19.2)  -0.8 
Insulin 5629 (7.4)  1302 (6.9)  1.9 1313 (7)  1280 (6.9)  0.7 
Antidepressants  [ZIP_CODE] (30)  5581 (29.4)  1.3 5529 (29.7)  5469 (29.4)  0.7 
Angiotensin II receptor 
blockers (ARBs)  [ZIP_CODE] (23.3)  4732 (24.9)  -3.8 4669 (25.1)  4650 (25)  0.2 
Angiotensin converting 
enzyme inhibitors (ACEi)  [ZIP_CODE] (32.5)  6081 (32)  1.1 5892 (31.6)  5973 (32.1)  -0.9 
Calcium channel blockers  [ZIP_CODE] (28.6)  5684 (30)  -3.1 5476 (29.4)  5588 (30)  -1.3 
Beta blockers  
[ZIP_CODE] (43.8)  8709 (45.9)  -4.1 8530 (45.8)  8547 (45.9)  -0.2 
Disease -modifying 
antirheumatic drugs 
(DMARDs) 2824 (3.7)  691 (3.6)  0.3 650 (3.5)  674 (3.6)  -0.7 
Diuretics 
[ZIP_CODE] (45.2)  8908 (46.9)  -3.4 8677 (46.6)  8751 (47)  -0.8 
Corticosteroids  [ZIP_CODE] (46.7)  7769 (40.9)  11.6 7603 (40.8)  7632 (41)  -0.3 
Antibiotics  
[ZIP_CODE] (76.1)  [ZIP_CODE] (67.5)  19.4 [ZIP_CODE] (67.5)  [ZIP_CODE] (67.6)  -0.2 
COPD specific covariates              
Respi[INVESTIGATOR_1399], n (%) 7994 (10.4)  2922 (15.4)  -14.8 2834 (15.2)  2865 (15.4)  -0.5 
Moderate or Severe COPD 
exacerbation, n (%)  3341 (4.4) 1181 (6.2)  -8.3 1174 (6.3)  1175 (6.3)  0 
Tuberculosis, n (%) [ZIP_CODE] (20.1)  4033 (21.3)  -2.8 3940 (21.1)  3992 (21.4)  -0.7 
Lung Cancer, n (%)  3415 (4.5)  1150 (6.1)  -7.2 1133 (6.1)  1130 (6.1)  0.1 
Bronchiectasis, n (%) 2207 (2.9)  820 (4.3)  -7.7 804 (4.3) 805 (4.3)  0 
Sarcoidosis, n (%)  [ZIP_CODE] (14.3)  3718 (19.6)  -14.1 3649 (19.6)  3659 (19.6)  -0.1 
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 17 Pulmonary Hypertension, 
n (%) 1643 (2.1)  627 (3.3)  -7.1 610 (3.3)  607 (3.3)  0.1 
Interstitial lung disease, 
lung fibrosis, ARDS, n (%)  [ZIP_CODE] (14.3)  3718 (19.6) -14.1 3649 (19.6)  3659 (19.6)  -0.1 
Acute Upper/ Lower 
Respi[INVESTIGATOR_740379], n (%)  
[ZIP_CODE] (30.8)  4249 (22.4)  19.2 4103 (22)  4175 (22.4)  -0.9 
Pneumonia, n (%)  6481 (8.5)  1734 (9.1)  -2.4 1703 (9.1)  1718 (9.2)  -0.3 
Alpha-1- antitrypsin 
deficiency, n (%) 84 (0.1)  37 (0.2)  -2.2 35 (0.2)  36 (0.2)  -0.[ADDRESS_1284684] 
visits, mean (SD)  0.9 (2.2)  1.6 (2.6) -27.2 1.6 (2.9) 1.6 (2.6) [ADDRESS_1284685], 
n (%) [ZIP_CODE] (29.7)  9742 (51.3)  -45.2 9806 (52.6)  9550 (51.3)  2.8 
Hierarchical COPD 
Medication, n (%)              
Monotherapy  
2536 (3.3)  1785 (9.4)  -25.2 1507 (8.1)  1726 (9.3)  -4.2 
Dual therapy  [ZIP_CODE] (72.6)  [ZIP_CODE] (57.3)  32.6 [ZIP_CODE] (59)  [ZIP_CODE] (58.4)  1.3 
Triple therapy [ZIP_CODE] (24)  6036 (31.8)  -17.4 6138 (32.9)  6034 (32.4)  1.2 
Comorbid conditions, n 
(%)             
Atrial fibrillation  [ZIP_CODE] (17.5)  3952 (20.8)  -8.4 3892 (20.9)  3892 (20.9)  0 
Heart failure  [ZIP_CODE] (18.6)  4218 (22.2)  -8.9 4137 (22.2)  4141 (22.2)  -0.1 
Stroke or transient 
ischemic attack 7776 (10.2)  1943 (10.2)  -0.3 1900 (10.2)  1905 (10.2)  -0.1 
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 18 Peripheral vascular 
disease [ZIP_CODE] (15.1)  3353 (17.7)  -6.9 3159 (17)  3299 (17.7)  -2 
Hyperlipi[INVESTIGATOR_035]  
[ZIP_CODE] (70.8)  [ZIP_CODE] (72.2)  -2.9 [ZIP_CODE] (71.9)  [ZIP_CODE] (72.1)  -0.5 
Renal dysfunction  [ZIP_CODE] (19.9)  3997 (21.1)  -3 3849 (20.7)  3917 (21)  -0.9 
Chronic liver disease  5263 (6.9)  1316 (6.9)  -0.2 1274 (6.8)  1287 (6.9)  -0.3 
Asthma  
[ZIP_CODE] (59.6)  [ZIP_CODE] (57.2)  4.9 [ZIP_CODE] (57.5)  [ZIP_CODE] (57)  0.9 
Ischemic heart disease [ZIP_CODE] (37.5)  7935 (41.8)  -8.8 7759 (41.6) 7791 (41.8)  -0.3 
Malignancy  [ZIP_CODE] (29.8)  6008 (31.7)  -4 5830 (31.3)  5896 (31.6)  -0.8 
Drug or alcohol abuse or 
dependence [ZIP_CODE] (26)  5549 (29.2)  -7.2 5436 (29.2)  5447 (29.2)  -0.1 
Venous 
thromboembolism  3418 (4.5)  915 (4.8)  -1.7 889 (4.8)  899 (4.8) -0.3 
Rheumatoid Arthritis  3666 (4.8)  913 (4.8)  -0.1 876 (4.7)  897 (4.8)  -0.[ADDRESS_1284686] ratios (1, 2, and 3 years) for the association between the treatment of interest and risk of ADRD after considering all-cause mortality as a competing 
event. Pre-specified subgroup analyses will be conducted based on age, sex, and baseline cardiovascular disease.  
 
  
DREAM study protocol  - Comparison 9 Salbutamol  versus Long-acting muscarinic antagonists  (LAMAs) 
 
 19 10. References 
 
1. Gothe H, Rajsic S, Vukicevic D, et al. Algorithms to identify COPD in health systems with and without access to ICD 
coding: a systematic review. BMC Health Serv Res. 2019;19(1):737. 
2.  GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE: Global Initiative for Chronic Obstructive Lung Disease; 2018. 
3. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. 
Biometrika. 1983;70(1):41-55. 
4. Rassen JA, Avorn J, Schneeweiss S. Multivariate -adjusted pharmacoepi[INVESTIGATOR_914334]. Pharmacoepi[INVESTIGATOR_65783]. 
2010;19(8):848-857.  
5. Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in 
cohort studies. Pharmacoepi[INVESTIGATOR_9697]. May 2012;[ADDRESS_1284687] 2:69-80. 
6. Austin PC. Some Methods of Propensity -Score Matching had Superior Performance to Others: Results of an 
Empi[INVESTIGATOR_358271]. Biometrical Journal. 2009;51(1):171-184. 
7. AM Walker AM, Patrick A, Lauer M, et al. Tool for Assessing the Feasibility of Comparative Effectiveness Research. 
Comp Effect Res 2013;3:11 -20. 
8. Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S. Metrics for covariate balance in cohort studies 
of causal effects. Statistics in medicine. May 10 2014;33(10):1685-1699.  
9. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. 
Circulation. 2016;133(6):601-609.  
 
 